| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9447106 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(9 years from now) | |
| US10927117 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(13 years from now) | |
| US11851437 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11142528 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(9 years from now) | |
| US10570139 | BEIGENE | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(9 years from now) | |
| US11884674 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(13 years from now) | |
| US11591340 | BEIGENE | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(13 years from now) | |
| US11701357 | BEIGENE | Treatment of B cell cancers using a combination comprising Btk inhibitors |
Jun, 2039
(15 years from now) | |
| US11911386 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(18 years from now) | |
| US11896596 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(18 years from now) | |
| US11786531 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(18 years from now) | |
Brukinsa is owned by Beigene.
Brukinsa contains Zanubrutinib.
Brukinsa has a total of 11 drug patents out of which 0 drug patents have expired.
Brukinsa was authorised for market use on 14 November, 2019.
Brukinsa is available in capsule;oral dosage forms.
Brukinsa can be used as treatment of adult patients with chronic lymphocytic leukemia (cll) who have received at least one prior therapy, treatment of adult patients with relapsed or refractory follicular lymphoma (fl), in combination with obinutuzumab, after two or more lines of systemic therapy, treatment of adult patients with small lymphocytic lymphoma, treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, treatment of adult patients with waldenstrom's macroglobulinemia (wm) receiving a moderate cyp3a inducer.
Drug patent challenges can be filed against Brukinsa from 15 November, 2023.
The generics of Brukinsa are possible to be released after 19 January, 2043.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
| New Indication(I-871) | Aug 31, 2024 |
| New Indication(I-936) | Mar 07, 2027 |
| New Indication(I-817) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
| New Indication(I-874) | Sep 14, 2024 |
| Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
| Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with small lymphocytic lymphoma; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with relaps...
Dosage: CAPSULE;ORAL
BRUKINSA family patents
